On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: PIB
Indian President Droupadi Murmu, on the occasion of World Sickle Cell Day 2026, today expressed confidence that the country can eradicate sickle cell disease well before the 2047 target.
Addressing the International Sickle Cell Day commemoration at Omkareshwar, Madhya Pradesh, President Murmu noted that the National Sickle Cell Anaemia Elimination Mission, launched in 2023, has so far "screened seven crore people, ranging from newborns to those up to 40 years of age."
Calling it "one of the largest initiatives for genetic disease screening in the world," she added that the mission has detected sickle cell disease "in approximately 2.5 lakh people so far, and over 20 lakh carriers of the disease have also been identified."
"Through the collective strength and active engagement of all states, we will succeed in achieving our national goal of eradicating sickle cell-related diseases from the country well before the year 2047," the President said.
The President highlighted three key dimensions of the mission:
She also stressed the need for collective efforts to raise awareness and eliminate the genetic blood disorder, particularly among tribal communities.
Also read: Sickle Cell Disease: Why India Must Add Curative Treatment to Meet Its 2047 Elimination Goal
Sickle cell disease is an inherited blood disorder that affects the shape and function of red blood cells. Instead of being round and flexible, the red blood cells become sickle- or crescent-shaped, making it difficult for them to move smoothly through blood vessels.
The chronic single-gene disorder causes a debilitating systemic syndrome characterized by chronic anemia, acute painful episodes, organ infarction, chronic organ damage, and a significant reduction in life expectancy.
"Sickle cell disease (SCD) is one of India’s most pressing inherited blood disorders, with an estimated 1 in 86 births among tribal and disadvantaged groups affected," Dr Manisha Madkaikar is Director - ICMR-National Institute for Research on Blood and Immune Disorders – Mumbai, told HealthandMe.
Children living with the condition often experience repeated hospital visits, missed school days and limitations in daily activities. Parents frequently face emotional distress, financial strain and the challenge of managing a lifelong medical condition.
Read More:No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
The National Sickle Cell Anaemia Elimination Program, introduced in the Union Budget 2023, focuses on addressing the significant health challenges posed by sickle cell disease, particularly among tribal populations in the country.
Implemented across 17 high-focus states, the programme aims to improve care and outcomes for sickle cell disease patients while reducing the prevalence of the disorder. The states are Gujarat, Maharashtra, Rajasthan, Madhya Pradesh, Jharkhand, Chhattisgarh, West Bengal, Odisha, Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Assam, Uttar Pradesh, Kerala, Bihar, and Uttarakhand.
Implemented in mission mode under the National Health Mission (NHM), the program aims to eliminate sickle cell genetic transmission by 2047.
Over a three-year period from 2023-24 to 2025-26, the program targets screening approximately seven crore people, promoting early diagnosis and intervention on a large scale.
Credit: @DNIGabbard/X
Did COVID-19 emerge naturally or from a laboratory leak? Nearly seven years after the pandemic began in late 2019, and despite more than 7.1 million confirmed deaths worldwide and numerous investigations, there is still no definitive answer about the virus's origins.
Now, Tulsi Gabbard, on her last day as the Director of National Intelligence, US, has reignited the debate by alleging that Anthony Fauci, who led the scientific and medical response to the COVID-19 pandemic in America, funded research at China's infamous Wuhan Institute of Virology that contributed to the pandemic.
"The COVID-19 pandemic caused tremendous hardship and pain for millions of Americans and countless people around the world," Gabbard said in a statement.
"After years of lies, censorship, and cover-ups, the American people deserve transparency, truth, and accountability."
According to Gabbard's office, the materials were released following a year-long declassification review conducted by the Office of the Director of National Intelligence (ODNI) as part of President Trump's transparency initiative.
During the review, officials reportedly gathered testimony from intelligence community whistleblowers who alleged they faced retaliation for challenging official assessments of the virus's origins.
Gabbard said the testimony revealed a pattern of suppressing dissenting views, discouraging debate, and sidelining evidence that conflicted with prevailing intelligence assessments.
Also read: COVID-19 Vaccination Reduced Risk of Heart Attacks and Strokes in Elderly by 40%: Study
According to Gabbard, the newly declassified communications and documents reveal that
Read More: 1 in 6 Americans May Be Suffering From Long COVID, Study Finds
Importantly, the declassified materials also include testimony from whistleblowers who claim analysts supporting the lab-leak theory faced professional consequences. These include:
Read: COVID Pandemic Left 55,000 Cancer Cases Undiagnosed In 7 Nations, Including Australia and the UK
Gabbard said these allegations have been referred to the intelligence community's inspector general for further review.
Whether the allegations lead to congressional hearings, legal action, or additional independent review remains uncertain.
Any conclusions will depend on careful examination of the documents, corroborating evidence, and responses from those named in the allegations. Fauci is yet to comment on the allegations.
Credit: iStock
The UK's human papillomavirus (HPV) vaccination program, initiated in 2018, has achieved a remarkable milestone: no women aged 20 to 24 died from cervical cancer in England between 2020 and 2024, according to a study published in the journal The Lancet.
England introduced the HPV vaccine for girls in 2008 and expanded the program to boys in 2019. By 2024, vaccine coverage among women aged 20-24 had reached nearly 90 per cent.
Researchers found that there were no cervical cancer deaths in this age group during the five-year period, compared with an estimated 23 deaths that would have been expected based on historical trends.
The study also estimated that HPV vaccination has prevented approximately 200 cervical cancer deaths among young women in England since the program began.
"It's amazing news that no women aged between 20 and 24 died from cervical cancer in the whole of England between 2020 and 2024," said Peter Sasieni, Professor of Cancer Epidemiology at Queen Mary University of London.
"That remarkable fact is thanks to nearly 90% of Gen Z women having received the HPV vaccine through the school vaccination and catch-up programs," he added.
This marks the first time that zero cervical cancer deaths have been recorded in this age group and provides compelling evidence of the vaccine's life-saving impact.
Read More: HPV Vaccine Can Help Curb Rising Head And Neck Cancers, Says Top US Doctor
The study found that girls vaccinated at ages 12-13 had an almost zero risk of dying from cervical cancer before the age of 30, highlighting the success of the school-based vaccination program.
While several countries have reported declines in cervical cancer rates following HPV vaccination campaigns, evidence linking vaccination programs directly to reductions in cervical cancer deaths has been limited.
"This is the first national-level evidence, albeit observational, linking high HPV vaccination coverage to a major reduction in cervical cancer deaths," the researchers noted.
Researchers analyzed HPV vaccination rates and cervical cancer mortality data among women in England between 2001 and 2024.
In addition to recording zero cervical cancer deaths among women aged 20-24 between 2020 and 2024, the study found an 80 per cent reduction in cervical cancer deaths in the same age group between 2015 and 2019.
The findings underscore the importance of achieving high vaccination coverage against a disease that remains one of the leading causes of cancer-related deaths among younger women worldwide.
"We estimate that since its introduction, HPV vaccination has prevented nearly 200 young women from dying from cervical cancer in England," said Sasieni.
"But that's just the tip of the iceberg. As vaccinated generations grow older, we'll see many more lives saved from cervical cancer. It is incredible to think that a single jab can almost eliminate a particular type of cancer."
Also read: Affordable India-Made HPV Test Offers Hope For Early Cervical Cancer Detection
The human papillomavirus (HPV) is the most common viral infection worldwide, with more than 200 known types. While some types lead to benign skin warts, others are responsible for severe health threats, such as cervical, throat, anal, and penile cancers. The HPV vaccine provides strong protection against the most lethal strains, avoiding long-term health complications.
The HPV vaccine helps the immune system recognize and fight off high-risk strains of the virus before they cause harm. It protects against:
© 2024 Bennett, Coleman & Company Limited